AbbVie scores speedy review for RA drug upadacitinib; Merck KGaA wins CRISPR patent
→ AbbVie $ABBV has high hopes, projecting peak potential sales of $6.5 billion, for its oral JAK1 inhibitor upadacitinib for rheumatoid arthritis, which is up against well-entrenched rivals. On Tuesday, the drugmaker said FDA had rewarded the drug — which is also under EU review — priority review, and that the US health regulator is expected to makes its decision by the third quarter of 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.